79 results on '"Hewlett JS"'
Search Results
2. ELLIPTOCYTOSIS
- Author
-
Weisman R, Mcbryde Rr, and Hewlett Js
- Subjects
Andrology ,Elliptocytosis ,Erythrocyte survival ,Chromium ,chemistry ,business.industry ,Medicine ,chemistry.chemical_element ,General Medicine ,business - Published
- 1956
3. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura
- Author
-
Bukowski, RM, King, JW, and Hewlett, JS
- Abstract
Two patients with thrombotic thrombocytopenic purpura (TTP) have recovered completely after intensive plasmapheresis. The mechanisms responsible for the improvement in these instances are most likely related to the removal of an inciting or damaging agent. The possibility that this agent may be an immune complex is discussed. Plasmapheresis appears to be useful therapy for some patients with this syndrome.
- Published
- 1977
- Full Text
- View/download PDF
4. Fluctuation of serum phenytoin concentrations during autologous bone marrow transplant for primary central nervous system tumors.
- Author
-
Ghosh C, Lazarus HM, Hewlett JS, and Creger RJ
- Subjects
- Adult, Astrocytoma drug therapy, Brain Neoplasms drug therapy, Carbamazepine therapeutic use, Female, Glioblastoma drug therapy, Humans, Lymphoma drug therapy, Male, Middle Aged, Phenytoin blood, Transplantation, Autologous, Anticonvulsants therapeutic use, Astrocytoma surgery, Bone Marrow Transplantation physiology, Brain Neoplasms secondary, Brain Neoplasms surgery, Glioblastoma surgery, Lymphoma surgery, Melanoma surgery, Phenytoin therapeutic use
- Abstract
We reviewed our experience for adult patients receiving oral anticonvulsant therapy during high-dose chemotherapy and autologous bone marrow re-infusion for primary malignant tumors of the central nervous system. Nineteen patients received either iv carmustine (BCNU) 900-1050 mg/m2 and 6120 cGy cranial irradiation (N = 10), iv carmustine 900-1050 mg/m2 and iv cisplatin 200 mg/m2 (N = 8), or iv carmustine 600 mg/m2, iv cisplatin 200 mg/m2, and iv etoposide 2400 mg/m2 (N = 1). Anticonvulsant therapy consisted of phenytoin alone (N = 8), phenobarbital alone (N = 4), carbamazepine alone (N = 2), phenytoin and carbamazepine (N = 2), carbamazepine and phenobarbital (N = 1), and no anticonvulsant therapy (N = 2). Serum anticonvulsant concentrations were monitored frequently and doses adjusted to keep values in the therapeutic range. While phenobarbital and carbamazepine doses remained relatively stable, all patients required increased doses of phenytoin anticonvulsant therapy after beginning chemotherapy (mean onset 3.7 days after initiation of chemotherapy). The increase in phenytoin dose ranged from 50% to 300% above baseline (mean 134%). By the time of discharge from the hospital (approximately 3-4 weeks after the start of chemotherapy) anticonvulsant dose was decreased to near pre-therapy levels. These swings coincided with the initiation of dexamethasone therapy for antiemetic effect and were more pronounced in patients also receiving cisplatin therapy. Due to close monitoring of serum phenytoin concentrations, no instances of toxicity due to excessive drug concentration, or seizures due to subtherapeutic doses, were noted in patients with primary CNS malignancies. Serum phenytoin concentrations fluctuate markedly during high-dose chemotherapy and must be analyzed frequently during the course of therapy.
- Published
- 1992
- Full Text
- View/download PDF
5. A case of large multilobated cell lymphoma.
- Author
-
Tubbs RR, Bauer TW, and Hewlett JS
- Subjects
- Adult, Cell Nucleus pathology, Female, Humans, Bone Neoplasms pathology, Lymphoma pathology, Skin Neoplasms pathology
- Published
- 1984
- Full Text
- View/download PDF
6. Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin.
- Author
-
Chernicoff D, Bukowski RM, Groppe CW Jr, and Hewlett JS
- Subjects
- Drug Therapy, Combination, Fluorouracil adverse effects, Humans, Streptozocin adverse effects, Adenoma, Islet Cell drug therapy, Carcinoid Tumor drug therapy, Fluorouracil therapeutic use, Intestinal Neoplasms drug therapy, Pancreatic Neoplasms drug therapy, Streptozocin therapeutic use
- Abstract
The results of combination chemotherapy with intermittent courses of 5-fluorouracil and streptozotocin in ten patients with metastatic carcinoid tumors and in eight patients with islet cell carcinoma are reported. Objective responses occurred in two of ten and in two of seven evaluable patients respectively. Biochemical responses occurred in an additional two patients with carcinoid. No improvement over single-agent chemotherapy and no effects on survival were noted.
- Published
- 1979
7. Therapy of adult acute leukemia with daunorubicin and L-asparaginase.
- Author
-
Bodey GP, Hewlett JS, Coltman CA Jr, Rodriguez V, and Freireich EJ
- Subjects
- Adolescent, Adult, Aged, Asparaginase administration & dosage, Daunorubicin administration & dosage, Drug Therapy, Combination, Female, Humans, Leukemia, Lymphoid mortality, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Remission, Spontaneous, Time Factors, Asparaginase therapeutic use, Daunorubicin therapeutic use, Leukemia, Lymphoid drug therapy, Leukemia, Myeloid, Acute drug therapy
- Published
- 1974
- Full Text
- View/download PDF
8. Randomized controlled trial of transfer factor in Stage II malignant melanoma.
- Author
-
Bukowski RM, Deodhar S, Hewlett JS, and Greenstreet R
- Subjects
- Adult, Clinical Trials as Topic, Female, Humans, Male, Melanoma surgery, Middle Aged, Neoplasm Metastasis, Prognosis, Prospective Studies, Random Allocation, Sex Factors, Skin Neoplasms surgery, Melanoma therapy, Skin Neoplasms therapy, Transfer Factor therapeutic use
- Abstract
Thirty-six patients with Stage II malignant melanoma were randomized to no further therapy or transfer factor (TF) following surgical removal of all evident disease. Eighteen patients received TF, and 18 were in the surgery only group. Median disease-free intervals were 12.0 and 10.0 months, and survival, 40.8 and 27.0 months, respectively. Nine TF patients and four control patients remain alive. These differences were not statistically significant, and no adjuvant effect of TF could be demonstrated.
- Published
- 1983
- Full Text
- View/download PDF
9. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.
- Author
-
Al-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, McCracken J, and Padilla F
- Subjects
- Cisplatin adverse effects, Humans, Kidney Diseases chemically induced, Kidney Diseases prevention & control, Water-Electrolyte Balance drug effects, Cisplatin administration & dosage, Mannitol administration & dosage, Melanoma drug therapy
- Abstract
In a prospective phase II randomized trial, a dose of 100 mg/m2 iv cisplatin every 3 weeks plus forced hydration with or without mannitol diuresis was tested in patients with previously treated advanced malignant melanoma. A total of 67 patients were evaluated: 33 not given mannitol and 34 in the mannitol arm. Two partial remissions (of 2+ and 6.5 months) were achieved in the no-mannitol arm and one complete response and four partial responses (of 1, 2, 2.5, 5.5, and 8 months) were seen in the mannitol arm. Moderate, severe, and life-threatening renal toxicity was less in the mannitol arm, and patients tolerated more doses of cisplatin. The renal toxicity occurred mostly after the first dose of chemotherapy and did not seem to be cumulative. Other side effects were comparable in both arms. We concluded that renal toxicity is less severe in patients treated with cisplatin, hydration, and mannitol and that the use of cisplatin alone or in combination with other active agent(s) should be considered for further evaluation in previously untreated patients with malignant melanoma.
- Published
- 1982
10. Adult acute leukemia studies utilizing cytarabine: early Southwest Oncology Group trials.
- Author
-
Coltman CA Jr, Freireich EJ, Pendleton O, Bickers JN, Bodey GP, Hewlett JS, and McCredie KB
- Subjects
- Adult, Clinical Trials as Topic, Cytarabine administration & dosage, Drug Therapy, Combination, Humans, Cytarabine therapeutic use, Leukemia drug therapy
- Published
- 1982
- Full Text
- View/download PDF
11. Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma.
- Author
-
Bukowski RM, Schacter LP, Groppe CW, Hewlett JS, Weick JK, and Livingston RB
- Subjects
- Adenocarcinoma mortality, Adult, Aged, Doxorubicin administration & dosage, Drug Evaluation, Drug Therapy, Combination, Female, Fluorouracil administration & dosage, Humans, Male, Middle Aged, Mitomycin, Mitomycins administration & dosage, Pancreatic Neoplasms mortality, Streptozocin administration & dosage, Adenocarcinoma drug therapy, Antineoplastic Agents administration & dosage, Pancreatic Neoplasms drug therapy
- Abstract
Twenty-five patients with unresectable and metastatic pancreatic carcinoma were treated with the combination of 5-fluorouracil, Adriamycin, mitomycin C and streptozotocin (FAM-S). Twelve of 25 patients responded (48%) and four patients demonstrated stable disease. Median survival of all patients was 6.75 months, and seven of 25 patients survived more than 12 months. Hematologic toxicity was moderate, and the predominant side effect recorded was nausea and vomiting (80% patients). Combination chemotherapy in pancreatic carcinoma may provide palliation and randomized trials are warranted to confirm these results.
- Published
- 1982
- Full Text
- View/download PDF
12. Progress in the treatment of adults with acute leukemia: review of regimens containing cytarabine studied by the Southwest Oncology Group.
- Author
-
Bodey GP, Coltman CA, Hewlett JS, and Freireich EJ
- Subjects
- Acute Disease, Adult, Cyclophosphamide administration & dosage, Cyclophosphamide therapeutic use, Cytarabine administration & dosage, Daunorubicin administration & dosage, Daunorubicin therapeutic use, Doxorubicin administration & dosage, Doxorubicin therapeutic use, Drug Therapy, Combination, Humans, Leukemia, Lymphoid drug therapy, Middle Aged, Prednisone administration & dosage, Prednisone therapeutic use, Vincristine administration & dosage, Vincristine therapeutic use, Cytarabine therapeutic use, Leukemia drug therapy
- Published
- 1976
13. Hepatic artery infusion with 5-fluorouracil and mitomycin-C in metastatic colorectal carcinoma phase II study.
- Author
-
Theodors A, Bukowski RM, Lavery I, Hewlett JS, Livingston RB, and Buonocore E
- Subjects
- Adult, Aged, Catheterization adverse effects, Colonic Neoplasms drug therapy, Drug Evaluation, Drug Therapy, Combination, Female, Fluorouracil adverse effects, Hepatic Artery, Humans, Infusions, Intra-Arterial, Liver Neoplasms drug therapy, Liver Neoplasms mortality, Male, Middle Aged, Mitomycin, Palliative Care, Random Allocation, Rectal Neoplasms drug therapy, Fluorouracil administration & dosage, Liver Neoplasms secondary, Mitomycins administration & dosage
- Abstract
Thirty-two patients with hepatic metastases colorectal carcinoma were treated with hepatic artery infusion (HAI) employing 5-fluorouracil (5-FU) and mitomycin-C (mito-C). Catheters were placed percutaneously via the femoral artery. Two schedules were employed: (I) 5-FU 1,200 mg/m2 IA (D1-4) and mito-C 8 mg/m2 IA (D1 + D4); (2) 5-FU 1,200 mg/m2 IA (D1-6) and mito-C 8 mg/m2 IA (D1 + D4). Courses were repeated every 4 weeks. Thirty patients with measurable disease were evaluable, 22 received schedule I and 8 patients schedule II. Complete response occurred in two patients (6.7%) and partial response in 13 patients (43.3%). Five patients (16.7%) had minimal regression. The overall response rate as 66.7%. Median survival of all patients from start of treatment was 11.2 months. Median survival of responders and nonresponders was 12.4 months and 4.6 months, respectively (P less than 0.05). No differences in response rates, duration of response, or survival was seen between the two schedules. Drug toxicity was moderate to severe, but morbidity of HAI per se was minimal. Intermittent HAI of 5-FU and mito-C is a well-tolerated treatment modality associated with few serious complications. The response rate, duration of response, and the survival is comparable to continuous HAI infusion of 5-FU or floxuridine (FUDR). As given in this study, mito-C did not appear to provide added benefit.
- Published
- 1982
- Full Text
- View/download PDF
14. Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma.
- Author
-
Smith GW, Bukowski RM, Hewlett JS, and Groppe CW
- Subjects
- Adult, Aged, Drug Administration Schedule, Female, Hepatic Artery, Humans, Infusions, Intra-Arterial, Male, Middle Aged, Mitomycin, Adenoma, Bile Duct drug therapy, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bile Duct Neoplasms drug therapy, Fluorouracil administration & dosage, Gallbladder Neoplasms drug therapy, Mitomycins administration & dosage
- Abstract
Eleven patients with histologically proven cholangiocarcinoma and gallbladder carcinoma were treated with hepatic artery infusion (HAI) of 5-fluorouracil (5-FU) and mitomycin C (Mito-C). Catheters were placed percutaneously through the femoral artery. The schedule used was 5-FU 1200/mg/m2/day given as a continuous infusion for 4 days, plus Mito-C 6 mg/m2 on days 1 and 4. Courses were repeated every 4 weeks. Complete responses (CR) occurred in one patient (9%), and partial response (PR) occurred in six patients (55%). Median survival for all patients from the start of the first treatment was 12.5+ months. Median duration of the response was 3.0 months. Median survival of the patients with gallbladder carcinoma was 12.5 months, and for patients with cholangiocarcinoma has not yet been reached. Drug toxicity was mild, and morbidity of the HAI was minimal. Further trials of chemotherapy in these two neoplasms are warranted.
- Published
- 1984
- Full Text
- View/download PDF
15. High dose BCNU with autologous bone marrow rescue in the treatment of recurrent malignant gliomas.
- Author
-
Mortimer JE, Hewlett JS, Bay J, and Livingston RB
- Subjects
- Adult, Carmustine adverse effects, Combined Modality Therapy, Dose-Response Relationship, Drug, Drug Therapy, Combination, Fluorouracil therapeutic use, Follow-Up Studies, Humans, Middle Aged, Bone Marrow Transplantation, Brain Neoplasms drug therapy, Carmustine therapeutic use, Glioblastoma drug therapy, Neoplasm Recurrence, Local drug therapy
- Abstract
Eleven patients with malignant gliomas recurring after surgery and radiation therapy, were treated with high dose BCNU 1 050-1 200 mg/M2 with autologous bone marrow rescue. Four patients also received concomitant 5-fluorouracil 1 000 mg/M2/24 hr daily for three days. Eight of ten evaluable patients demonstrated improvement on CAT scan as well as a decrease in steroid requirement. All patients surviving longer than two weeks after BCNU administration experienced full hematologic recovery. No delayed myelosuppression was seen after a single course of high dose therapy. Two patients died as a result of therapy, one following a second induction of BCNU for a total cumulative BCNU dose of 2 400 mg/M2 and one of infection while cytopenic. Additional toxicity includes one steroid-responsive interstitial pneumonitis, one centrilobular necrosis of the liver which spontaneously resolved and one episode of deep vein thrombosis. With limitation on the maximum BCNU dose and distribution of the total dose over three days, high dose BCNU can be administered with acceptable toxicity. This approach may offer a higher response rate than that expected for standard dose BCNU.
- Published
- 1983
- Full Text
- View/download PDF
16. The therapy of malignant melanoma with transfer factor. A preliminary report.
- Author
-
Price FB, Hewlett JS, Deodhar SD, and Barna B
- Subjects
- Cytotoxicity Tests, Immunologic, Humans, Hypersensitivity, Delayed, Immunity, Cellular, T-Lymphocytes immunology, Immunity, Maternally-Acquired, Immunotherapy, Melanoma therapy
- Published
- 1974
- Full Text
- View/download PDF
17. Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study.
- Author
-
Theodors A, Bukowski RM, Hewlett JS, Livingston RB, and Weick JK
- Subjects
- Aged, Ampulla of Vater, Antibiotics, Antineoplastic administration & dosage, Celiac Artery, Common Bile Duct Neoplasms drug therapy, Doxorubicin administration & dosage, Drug Administration Schedule, Drug Evaluation, Drug Therapy, Combination, Female, Fluorouracil administration & dosage, Humans, Infusions, Intra-Arterial, Male, Middle Aged, Mitomycin, Mitomycins administration & dosage, Streptozocin administration & dosage, Adenocarcinoma drug therapy, Antineoplastic Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols, Pancreatic Neoplasms drug therapy
- Abstract
Nineteen patients with unresectable and metastatic adenocarcinoma of the pancreas and ampulla of Vater were treated with intermittent regional infusion of the celiac axis (CAI) with the combination of 5-fluorouracil, adriamycin, mitomycin-C, and streptozotocin (FAM-S). Three schedules with escalating doses were investigated. The arterial infusion was repeated at 4 weeks, and in responding and stable patients, I.V. FAM-S was continued at monthly intervals. Twelve patients had measurable disease, and in this group one complete response and seven partial responses occurred. Median duration of response was 6+ months and median survival for all patients was 5.2 months. Four patients had catheter-related complications (emboli, three, sepsis, one). Hematologic and gastrointestinal toxicity was minimal. Celiac artery infusion with FAM-S in locally extensive and metastatic adenocarcinoma of the pancreas and ampulla of Vater is a relatively simple procedure associated with low incidence of serious complications and toxicity but a higher response rate than previously reported. Induction of response with CAI and subsequent maintenance therapy with intravenous chemotherapy is under investigation.
- Published
- 1982
18. Successful treatment of bleomycin lung.
- Author
-
Brown LD, Reimer RR, Ahmad M, and Hewlett JS
- Subjects
- Adult, Humans, Male, Middle Aged, Pulmonary Fibrosis chemically induced, Bleomycin adverse effects, Prednisone therapeutic use, Pulmonary Fibrosis drug therapy
- Published
- 1980
- Full Text
- View/download PDF
19. Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas.
- Author
-
Bukowski RM, Abderhalden RT, Hewlett JS, Weick JK, and Groppe CW Jr
- Subjects
- Drug Evaluation, Drug Therapy, Combination, Fluorouracil adverse effects, Humans, Mitomycins adverse effects, Nausea chemically induced, Streptozocin adverse effects, Thrombocytopenia chemically induced, Vomiting chemically induced, Adenocarcinoma drug therapy, Fluorouracil administration & dosage, Mitomycins administration & dosage, Pancreatic Neoplasms drug therapy, Streptozocin administration & dosage
- Abstract
A phase II study study employing 5-fluorouracil, mitomycin C, and streptozotocin in unresectable pancreatic carcinoma was performed. Seven of 22 patients (32%) responded and 4 of 22 (18%) had stable disease. Median survival of the entire group was 6 months, and of responders 9.5 months. In 13 patients with localized disease, five responses (38%) were seen and median survival was 7.5 months. Toxicity of the regimen was moderate, being predominantly gastrointestinal and renal. The usefulness of this regimen in localized pancreatic cancer should be explored further.
- Published
- 1980
20. Cytarabine for acute leukemia in adults. Effect of schedule on therapeutic response.
- Author
-
Bickers JN, Gehan EA, Freireich EJ, Coltman CA Jr, Wilson HE, Hewlett JS, Stuckey WJ, and Van Slyck EJ
- Subjects
- Acute Disease, Adult, Blood Cell Count, Blood Platelets, Cytarabine administration & dosage, Female, Hemoglobinometry, Humans, Infusions, Parenteral, Leukemia blood, Leukemia, Lymphoid drug therapy, Leukemia, Myeloid drug therapy, Leukemia, Myeloid, Acute drug therapy, Male, Middle Aged, Neoplasm Regression, Spontaneous, Remission, Spontaneous, Sex Factors, Time Factors, Cytarabine therapeutic use, Leukemia drug therapy
- Published
- 1974
- Full Text
- View/download PDF
21. Simultaneous treatment with cisplatin and radiation therapy for advanced solid tumors: a pilot study.
- Author
-
Reimer RR, Gahbauer R, Bukowski RM, Hewlett JS, Groppe CW Jr, Weick JK, and Antunez AR
- Subjects
- Cisplatin adverse effects, Drug Administration Schedule, Humans, Melanoma drug therapy, Melanoma radiotherapy, Neoplasm Metastasis, Neoplasms pathology, Neoplasms radiotherapy, Pilot Projects, Prognosis, Radiotherapy adverse effects, Radiotherapy Dosage, Cisplatin therapeutic use, Neoplasms drug therapy
- Abstract
To study the toxicity and efficacy of simultaneous cisplatin chemotherapy and radiation therapy, 13 patients with metastatic solid tumors were treated with cisplatin on a weekly, outpatient basis during palliative radiation therapy. The dose of cisplatin ranged from 20 to 50 mg/m2 weekly, with most patients receiving 40 mg/m2. Radiation therapy was administered in a variety of dose-fraction schedules. Toxic effects were moderate and consisted of emesis (12 patients), transient elevation off BUN (three patients), myelosuppression (three patients), and radiation reactions (two patients). Twelve of 13 irradiated lesions (91%) responded with at least a 50% reduction in biperpendicular diameter. Four of the six patients with metastatic melanoma had complete regression of treated lesions; another melanoma patient had a partial response. Responses were also seen in patients with mesothelioma, bladder cancer, squamous cell carcinoma of the head and neck, and oat cell lung cancer. Only one responding patient has had disease progression in the treated field after 2+ to 7+ months of followup; two other patients have died of disseminated disease. Weekly cisplatin administration during radiotherapy deserves further evaluation, especially in the primary management of unresectable tumors that are responsive to cisplatin alone.
- Published
- 1981
22. Adriamycin therapy in previously treated adult acute leukemia.
- Author
-
Wilson HE, Bodey GP, Moon TE, Amare M, Bottomley R, Haut A, Hewlett JS, Morrison F, and Saiki JH
- Subjects
- Acute Disease, Adult, Aged, Clinical Trials as Topic, Doxorubicin adverse effects, Humans, Middle Aged, Remission, Spontaneous, Time Factors, Doxorubicin therapeutic use, Leukemia drug therapy
- Published
- 1977
23. Phase II trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study.
- Author
-
Thigpen JT, Al-Sarraf M, and Hewlett JS
- Subjects
- Adult, Aged, Bone Marrow drug effects, Dianhydrogalactitol administration & dosage, Dianhydrogalactitol toxicity, Digestive System drug effects, Drug Evaluation, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Dianhydrogalactitol therapeutic use, Melanoma drug therapy, Sugar Alcohols therapeutic use
- Abstract
Dianhydrogalactitol given iv in a schedule of 30 mg/m2/day for 5 consecutive days every 4 weeks was administered to 27 patients with metastatic malignant melanoma. All patients had received extensive prior therapy including chemotherapy and had progressive disease at the start of the study. Of 24 patients evaluable for response, 21 demonstrated progressive disease and three had stable disease for periods of from 4 to 11 months. No objective responses were observed. Two of the remaining three patients died 6 and 10 days after entry in the study, while the third refused to return after one drug course. Adverse effects included myelosuppression in eight patients, nausea and vomiting in five patients, and alopecia in one patient. Dianhydrogalactitol is considered to be insignificantly active in the secondary treatment of metastatic malignant melanoma at the dose and schedule studied.
- Published
- 1979
24. Macroglobulinemia and malabsorption.
- Author
-
Tubbs RR, McLaughlin JP, Winkelman EI, Deodhar SD, and Hewlett JS
- Subjects
- Female, Humans, Jejunum pathology, Lymph Nodes pathology, Lymphangiectasis, Intestinal pathology, Middle Aged, Malabsorption Syndromes pathology, Waldenstrom Macroglobulinemia pathology
- Published
- 1977
- Full Text
- View/download PDF
25. Chemotherapy of acute leukemia. Comparison of cytarabine alone and in combination with vincristine, prednisone, and cyclophosphamide.
- Author
-
Bodey GP, Coltman CA, Freireich EJ, Bonnet JD, Gehan EA, Haut AB, Hewlett JS, McCredit KB, Saiki JH, and Wilson HE
- Subjects
- Acute Disease, Adolescent, Adult, Age Factors, Aged, Anemia chemically induced, Chemical and Drug Induced Liver Injury, Child, Child, Preschool, Cyclophosphamide toxicity, Cytarabine toxicity, Drug Therapy, Combination, Female, Humans, Leukemia, Lymphoid drug therapy, Leukemia, Myeloid, Acute drug therapy, Leukocyte Count, Leukopenia chemically induced, Male, Middle Aged, Nausea chemically induced, Prednisone toxicity, Time Factors, Vincristine toxicity, Vomiting chemically induced, Cyclophosphamide therapeutic use, Cytarabine therapeutic use, Leukemia drug therapy, Prednisone therapeutic use, Vincristine therapeutic use
- Published
- 1974
- Full Text
- View/download PDF
26. Mast cells in aplastic anemia.
- Author
-
Savage RA, Hamburger SA, Hewlett JS, and Doering E
- Subjects
- Adolescent, Anemia, Aplastic therapy, Cell Count, Humans, Mast Cells transplantation, Anemia, Aplastic pathology, Mast Cells pathology
- Published
- 1979
- Full Text
- View/download PDF
27. Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study.
- Author
-
Saiki JH, Bodey GP, Hewlett JS, Amare M, Morrison FS, Wilson HE, and Linman JW
- Subjects
- Acute Disease, Adult, Azacitidine adverse effects, Drug Administration Schedule, Drug Evaluation, Female, Humans, Male, Remission, Spontaneous, Time Factors, Azacitidine administration & dosage, Leukemia drug therapy
- Abstract
One-hundred-fifty-four patients with acute leukemia and extensive prior chemotherapy were treated with 5-Azacytidine and evaluated according to five different schedules. One-hundred-twenty patients received adequate trials; 34 patients died within 14 days of onset of treatment. Nine patients achieved a complete remission (CR) and two achieved a partial remission. Although two of the treatments have a higher remission rate, the data were not statistically significant. The median time to CR was 48 days (range 21-173). The median duration of CR was 65 days (range 39-369). There was no difference in response rate according to cell type. The median age of responders was 31 years, and 39 years for nonresponders. Proportionately there were more women among responders (5M/6F) and more men (70M/39F) among nonresponders. At onset of therapy the median leukocyte counts were similar between responding (5.4 X 10(3)) and nonresponding (5.7 X 10(3)) patients, but the proportion of leukemic cells was significantly higher among nonresponding patients (46% vs. 7%). Toxicities included nausea, vomiting, diarrhea, skin rash, myalgias, prolonged myelosuppression, hypotension, and central nervous system stupor and/or coma. Lower dose continuous infusion schedules of five-, seven-, and ten-days duration appear effective and were associated with less toxicity.
- Published
- 1981
- Full Text
- View/download PDF
28. Management of adult acute leukemia. A Southwest Oncology Group study.
- Author
-
McCredie KB, Gehan EA, Freireich EJ, Hewlett JS, Coltman CA Jr, Hussein KK, Balcerzak SP, and Chen TT
- Subjects
- Acute Disease, Adult, BCG Vaccine therapeutic use, Drug Therapy, Combination, Female, Humans, Leukemia mortality, Leukemia pathology, Leukocyte Count, Male, Middle Aged, Platelet Count, Prognosis, Retrospective Studies, Time Factors, Antineoplastic Agents administration & dosage, Leukemia drug therapy
- Abstract
Five hundred forty three adult patients with acute leukemia were entered on the study designed to: (1) test efficacy of vincristine and prednisone used as primary drug therapy in patients with good prognosis as judged by a circulating blast cell count less than 30,000 cm2; (2) investigate the use of either simultaneously or sequentially administered Adriamycin plus cytosine arabinoside plus vincristine and prednisone; and (3) to assess the use of bacillus Calmette-Guerin (BCG) in the maintenance phase on both the response and duration of response. Complete remissions were seen in 21% of patients with the vincristine and prednisone arm. Complete remission rates were similar in both the simultaneously and sequentially administered chemotherapy with overall complete remission rates of 55%. Median durations of complete remission and survival were 35 and 62 weeks, respectively, for patients with AML; and 47 and 75, respectively, for patients with ALL. Toxicity was within acceptable limits. BCG administered during the maintenance phase of therapy caused no differences in duration of complete remission and survival. These results demonstrate an improved response and duration of response over previous studies done by this group.
- Published
- 1983
- Full Text
- View/download PDF
29. High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine.
- Author
-
Hewlett JS, Chen T, Balcerzak SP, Gutterman JU, Costanzi JJ, and Amare M
- Subjects
- Acute Disease, Adolescent, Adult, Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Clinical Trials as Topic, Cytarabine administration & dosage, Female, Humans, Leukemia pathology, Leukemia, Lymphoid drug therapy, Leukemia, Myeloid, Acute drug therapy, Male, Middle Aged, Prednisone administration & dosage, Random Allocation, Sex Factors, Time Factors, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, BCG Vaccine administration & dosage, Leukemia drug therapy
- Abstract
In this Southwest Oncology Group (SWOG) study, 216 adults with acute leukemia were treated with ten-day chemotherapy consisting of vincristine sulfate (Oncovin), cytarabine (ara-C) (100 mg per square meter of body area per day by 24-hour infusion), and prednisone (ten-day OAP). The results were compared with those of a previous SWOG study in which cytarabine (200 mg per square meter of body area per day) was given for five days (five-day OAP). Patients entering complete remission (CR) were given three consolidation courses of five-day OAP and randomized to maintenance chemotherapy alone (32 patients) or combined with BCG vaccine (24 patients). For 160 previously untreated patients with acute myelogenous leukemia, there was no difference in remission rates (53% vs 43%) or median survival times (48 vs 47 weeks) between ten-day and five-day OAP. The difference in duration of CR (74 vs 54 weeks, respectively) between the two maintenance arms was not statistically significant. However, 14% of evaluable patients with acute myelogenous leukemia and 26% of those achieving CR were alive and in remission more than five years.
- Published
- 1985
30. Treatment of severe aplastic anemia with antithymocyte globulin.
- Author
-
Rothmann SA, Streeter RR, Bukowski RM, and Hewlett JS
- Subjects
- Acute Disease, Adult, Anemia, Aplastic blood, Anemia, Aplastic mortality, Child, Child, Preschool, Colony-Forming Units Assay, Erythropoiesis, Female, Humans, Leukocyte Count, Lymphocytes, Male, Middle Aged, Platelet Count, Prednisone therapeutic use, Anemia, Aplastic therapy, Antilymphocyte Serum therapeutic use, T-Lymphocytes immunology
- Abstract
Eleven patients with acute-onset (less than 2 months), severe aplastic anemia were treated with antithymocyte globulin (ATG) at a total dose between 50 and 420 mg/kg. Median age was 27 (5-74) years. Two additional patients with chronic severe aplastic anemia received ATG but were excluded from analysis after development of bone marrow morphologic and cytogenetic abnormalities suggestive of acute leukemia. Of the 11 analyzed patients, 5 died within 6 months after initial ATG treatment. Six patients, or 54 percent, survived with a minimum follow-up of 24 months and the longest 48 months. Median survival is 42 months. All patients are transfusion-independent although none are completely normal, due to mild thrombocytopenia. The in vitro effect of ATG on pretreatment marrow CFUE was determined in 8 patients and concordance with clinical outcome was observed for only 3 patients. Three patients had no in vitro response and survived, and 2 patients had a positive in vitro response and died. Survival after ATG correlated with maximum percent decrease in absolute lymphocyte count during treatment. No significant correlation was determined for any other parameter. The mechanism of ATG action remains unknown but the clinical response suggests that immune dysfunction may play an important role in the development or prolongation of aplastic anemia, and that this abnormality may be reversible by ATG in some patients.
- Published
- 1982
31. Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma.
- Author
-
McKelvey EM, Luce JK, Talley RW, Hersh EM, Hewlett JS, and Moon TE
- Subjects
- Drug Therapy, Combination, Eosinophils, Female, Humans, Leukocyte Count, Lymphocytes, Male, Melanoma blood, Melanoma immunology, Neoplasm Metastasis, Remission, Spontaneous, Carmustine therapeutic use, Dacarbazine therapeutic use, Melanoma drug therapy, Triazenes therapeutic use, Vincristine therapeutic use
- Abstract
One hundred thirty two patients with disseminated malignant melanoma were treated using a combination of BCNU, vincristine and imidazole carboxamide. A response rate of 23% was observed, while 16% had stable disease. The patients' median survival was 42 months from diagnosis and 5.3 months from the onset of treatment. These results are not significantly different from therapy with imidazole carboxamide alone. Patients on this study were observed to have a significant reduction in the number of lymphocytes in their peripheral blood (mean 1800/mm3, median 1550/mm3). Patients with lymphopenia prior to the onset of therapy (86%) had a similar response rate but a shorter median survival (4.4 months vs. 7.8 months, P = .03) than patients with normal lymphocyte levels. These findings are compatible with recent observations on the importance of host immunocompetence in patients with malignant melanoma. Eosinophil levels were not closely correlated with response, although among patients with eosinophil counts of greater than 300/mm3 (22%), a slightly higher response rate (29%) was observed (P = .13). Eosinophilia did not influence patient survival.
- Published
- 1977
- Full Text
- View/download PDF
32. Prognostic factors in multiple myeloma.
- Author
-
Alexanian R, Balcerzak S, Bonnet JD, Gehan EA, Haut A, Hewlett JS, and Monto RW
- Subjects
- Aged, Anemia etiology, Drug Therapy, Combination, Female, Humans, Hypercalcemia etiology, Immunoglobulins analysis, Male, Melphalan therapeutic use, Middle Aged, Multiple Myeloma blood, Multiple Myeloma drug therapy, Multiple Myeloma immunology, Multiple Myeloma pathology, Myeloma Proteins, Plasma Cells pathology, Prednisone therapeutic use, Prognosis, Remission, Spontaneous, Serum Albumin, Time Factors, Uremia etiology, Multiple Myeloma mortality
- Abstract
The effect of certain disease parameters on remission and survial time was evaluated in 482 patients with multiple myeloma treated with intermittent courses of melphalan-prednisone combinations. Increasing degrees of anemia, hypercalcemia, azotemia, and high serum myeloma protein levels were associated with progressive lifespan shortening. The short survival of patients with anemia and hypercalcemia was associated with short remissions in responding patients with these abnormalities. The extent of tumor mass was defined from specific laboratory parameters reported by Durie to be associated with large numbers of plasma cells. More advanced stages of myeloma were associated with higher frequencies and degrees of normal immunoglobulin depression. The response rate was not affected by the tumor mass grade, but increasing tumor mass was associated with a shorter lifespan. Greater degrees of tumor reduction were associated with longer remission and survival times. Patients in whom a marked tumor reduction was rapid had shorter survival and remission times than patients who responded more slowly.
- Published
- 1975
- Full Text
- View/download PDF
33. IgM monoclonal gammopathy. Histopathologic and clinical spectrum.
- Author
-
Tubbs RR, Hoffman GC, Deodhar SD, and Hewlett JS
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Hypergammaglobulinemia diagnosis, Hypergammaglobulinemia immunology, Hypergammaglobulinemia pathology, Immunoglobulin M
- Published
- 1976
- Full Text
- View/download PDF
34. 5-azacytidine in acute leukemia.
- Author
-
Saiki JH, McCredie KB, Vietti TJ, Hewlett JS, Morrison FS, Costanzi JJ, Stuckey WJ, Whitecar J, and Hoogstraten B
- Subjects
- Acute Disease, Adult, Azacitidine administration & dosage, Azacitidine adverse effects, Bone Marrow drug effects, Central Nervous System drug effects, Female, Humans, Leukemia, Lymphoid drug therapy, Leukemia, Myeloid, Acute drug therapy, Male, Remission, Spontaneous, Time Factors, Azacitidine therapeutic use, Leukemia drug therapy
- Abstract
101 patients with acute leukemia in relapse were treated with 5-azacytidine according to three schedules: Regimen A--300 mg/m2(day divided intravenously at 8 hour intervals for 5 days; Regimen B--750 mg/m2 as a single iv pulse dose administered at 2 to 3 weeks intervals; and Regimen C--300 mg/m2/day by continuous infusion daily for 5 days. Twelve patients achieved a complete remission (CR) and six achieved a partial remission (PR) for an overall 18% response rate. Of 78 patients receiving an adequate trial the response rate was 23%. An average of 1.5 courses and a median of 5 weeks were necessary to achieve a response. The median duration of CR patients was 21 weeks and for PR patients it was 5 weeks. Response rates were 24% for Regimen A, 0 for Regimen B, and 1 of 8 for Regimen C. The CR rate for AML and AMML was 13%. Two of eight AMoL patients achieved a CR. Only 2 of 23 ALL patients responded, one of whom achieved a CR. Toxicity included moderate to severe nausea and vomiting, diarrhea, stomatitis, skin rash, and prolonged myelosuppression. 5-azacytidine has significant activity in the acute nonlymphoblastic leukemias.
- Published
- 1978
- Full Text
- View/download PDF
35. Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission.
- Author
-
Tallman MS, Kopecky KJ, Amos D, Dahlberg S, Hewlett JS, Files JC, Coltman CA, Thomas ED, and Appelbaum FR
- Subjects
- Adolescent, Adult, Age Factors, Child, Child, Preschool, Combined Modality Therapy, Female, Humans, Infant, Leukemia, Myeloid, Acute therapy, Male, Middle Aged, Prognosis, Regression Analysis, Remission Induction, Sex Factors, Whole-Body Irradiation, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow Transplantation, Leukemia, Myeloid, Acute mortality
- Abstract
To test whether variables at diagnosis can identify patients with acute nonlymphoblastic leukemia (ANL) for whom bone marrow transplantation (BMT) is more likely to be of benefit and those for whom continued chemotherapy is a better approach, the association of 15 clinical and laboratory factors with outcome was investigated among 220 patients (ages 1 to 53 years) treated with cyclophosphamide and total body irradiation (TBI) followed by allogeneic BMT, and among 392 patients (ages 13 to 50) administered intensive chemotherapy. In the BMT group, female sex, younger age, the absence of hepatitis during induction, a larger percentage of circulating blasts, and a shorter duration of symptoms were associated with longer survival, whereas only female sex and younger age favorably influenced disease-free survival (DFS). In the chemotherapy group, younger age, lower WBC at diagnosis, a single successful induction course, and the absence of circulating promyelocytes were associated with longer survival, whereas only a lower WBC and a lower percentage of peripheral neutrophils were associated with longer DFS. Estimated regression coefficients for treatment-by-prognostic-factor interactions were used to characterize subgroups of patients in which one treatment or the other produced better outcomes. BMT and chemotherapy produced similar durations of survival in a subset of patients characterized by many or all of the following: older age, male sex, achievement of complete remission (CR) after one induction, and absence of circulating blast cells at presentation. These data suggest that, using pretreatment variables, subgroups of patients can be identified for whom either BMT or continued chemotherapy is most likely to be beneficial.
- Published
- 1989
- Full Text
- View/download PDF
36. Immunotherapy of disseminated renal cell carcinoma with transfer factor.
- Author
-
Montie JE, Bukowski RM, Deodhar SH, Hewlett JS, Stewart BH, and Straffon RA
- Subjects
- Adenocarcinoma immunology, Humans, Immunotherapy, Kidney Neoplasms immunology, Lymphocyte Activation, Neoplasm Metastasis, Adenocarcinoma therapy, Kidney Neoplasms therapy, Transfer Factor therapeutic use
- Abstract
Ten patients with disseminated renal cell carcinoma have been treated with transfer factor as an immunostimulant. In 5 patients with metastatic disease evident at the time of initial diagnosis treatment involved removal of the primary tumor followed by transfer factor therapy. Of these patients 3 had a temporary stabilization of metastatic disease. Three patients with recurrent metastatic disease after previous nephrectomy were treated, 2 of whom showed a temporary stabilization of metastatic disease. There were 2 additional patients without clinically evident metastases but at a high risk for recurrent disease who were treated and remain free of disease. We used 5 immunologic parameters to evaluate the clinical effects of transfer factor. No objective clinical regression was noted in any patient treated with measurable disease.
- Published
- 1977
- Full Text
- View/download PDF
37. Cyclocytidine chemotherapy for malignant melanoma.
- Author
-
McKelvey EM, Hewlett JS, Thigpen T, and Whitecar J
- Subjects
- Ancitabine adverse effects, Clinical Trials as Topic, Humans, Neoplasm Metastasis, Ancitabine therapeutic use, Cytarabine analogs & derivatives, Melanoma drug therapy
- Abstract
Twenty-nine patients with metastatic malignant melanoma were treated with cyclocytidine, 240 mg/m2/day sc for 10 days. All partients had received extensive prior chemotherapy. Only one patient achieved a partial remission; the overall response rate (complete plus partial) was 4%. Unusual toxic effects associated with cyclocytidine chemotherapy included the delayed onset of thrombocytopenia, orthostatic hypotension, and jaw pain.
- Published
- 1978
38. T and B lymphocytes in non-Hodgkin's lymphoma: a comparison of tumor-derived cells and peripheral blood lymphocytes.
- Author
-
Noguchi S, Bukowski R, Deodhar S, and Hewlett JS
- Subjects
- Cell Separation, Complement System Proteins, Humans, Immune Adherence Reaction, Immunoglobulin A analysis, Immunoglobulin G analysis, Immunoglobulin M analysis, Lectins, Lymph Nodes pathology, Lymphocyte Activation, Receptors, Antigen, B-Cell analysis, Skin Tests, B-Lymphocytes pathology, Lymphoma pathology, T-Lymphocytes pathology
- Abstract
T- and B-cell markers of lymphocytes in peripheral blood, involved node and spleen, PHA response of peripheral blood lymphocytes, serum immunoglobulin levels, and skin test reactivity to six common antigens were studied in 16 cases of untreated non-Hodgkin's lymphoma. Impaired response of peripheral lymphocytes to PHA was observed in 13 of 16 cases, regardless of the proportion of T lymphocytes. Of 12 cases in which skin tests were done, two were positive and had a normal PHA response, seven cases were positive in spite of low PHA response, and three were negative with low PHA response. In the lymph nodes from involved areas two cases showed monoclonal increase of B-cells, five showed "null" cell increase, and the remaining nine showed no increase or decrease of subpopulation of lymphocytes. No correlation with surface marker of lymphocytes to histologic classification was seen. From the above observations it was concluded: 1) a low PHA response in non-Hodgkin's lymphoma was not due to the decreased population of T-cells; 2) a low PHA response may not necessarily indicate impaired delayed hypersensitivity; and 3) non-Hodgkin's lymphoma can be classified in the following ways--B-cell proliferative type, "null" cell increase type, and normal T/B proportion type.
- Published
- 1976
- Full Text
- View/download PDF
39. Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.
- Author
-
Baker LH, Saiki JH, Jones SE, Hewlett JS, Brownlee RW, Stephens RL, and Vaitkevicius VK
- Subjects
- Adult, Aged, Doxorubicin adverse effects, Drug Evaluation, Drug Therapy, Combination, Female, Fluorouracil adverse effects, Humans, Male, Middle Aged, Carcinoma, Hepatocellular drug therapy, Doxorubicin therapeutic use, Fluorouracil therapeutic use, Liver Neoplasms drug therapy
- Published
- 1977
40. Chemotherapy of acute leukemia: a comparison of vincristine, cytarabine, and prednisone alone and in combination with cyclophosphamide or daunorubicin.
- Author
-
Coltman CA Jr, Bodey GP, Hewlett JS, Haut A, Bickers J, Balcerzak SP, Costanzi JJ, Freireich EJ, McCredie KB, Groppe C, Smith TL, and Gehan EA
- Subjects
- Acute Disease, Adult, Aged, Cyclophosphamide administration & dosage, Cytarabine administration & dosage, Daunorubicin administration & dosage, Drug Therapy, Combination, Evaluation Studies as Topic, Female, Humans, Male, Middle Aged, Prednisone administration & dosage, Remission, Spontaneous, Time Factors, Vincristine administration & dosage, Antineoplastic Agents administration & dosage, Leukemia drug therapy
- Abstract
Adults (274) with acute leukemia (AML) were randomly assigned to one of three treatment regimens: vincristine, prednisone, cytarabine--(1) 100 mg/sq m/day with cyclophosphamide (COAP); (2) 100 mg/sq m/day with daunorubicin (DOAP); and 200 mg/sq m/day (OAP). Cytarabine was infused continuously for five days. Patients entering complete remission randomly received maintenance treatment with COAP or OAP. For 197 previously untreated AML patients given COAP, DOAP, or OAP, remission rates were 37%, 35%, and 43%, respectively; median lengths, 40, 45, and 90 weeks; median survival, 7, 11, and 8 weeks. No statistically significant difference was found among treatments. Therefore, adding cyclophosphamide or daunorubicin, or using the COAP regimen with continuously infused cytarabine, produced no significant improvement over previously reported regimens. There was no significant difference in remission lengths in previously untreated AML patients maintained on OAP (median 81 weeks) or COAP (median 65 weeks).
- Published
- 1978
- Full Text
- View/download PDF
41. Combination 6-mercaptopurine and 6-methylmercaptopurine riboside in the treatment of adult acute leukemia: a Southwest Oncology Group study.
- Author
-
Hewlett JS, Bodey GP, Wilson HE, and Stuckey WJ
- Subjects
- Acute Disease, Adolescent, Adult, Aged, Clinical Trials as Topic, Drug Therapy, Combination, Female, Humans, Male, Mercaptopurine adverse effects, Methylthioinosine adverse effects, Middle Aged, Time Factors, Inosine analogs & derivatives, Leukemia drug therapy, Mercaptopurine therapeutic use, Methylthioinosine therapeutic use
- Published
- 1979
42. SPLEEN/PATHOL.
- Author
-
Bukowski RM, Noguchi S, Hewlett JS, and Deodhar S
- Subjects
- Hodgkin Disease immunology, Hodgkin Disease pathology, Humans, Hyperplasia pathology, Hypersensitivity, Delayed, Immunity, Cellular, Lectins pharmacology, Leukocyte Count, Lymph Nodes pathology, Lymphocyte Activation, Mitogens pharmacology, Spleen pathology, B-Lymphocytes analysis, Hodgkin Disease blood, T-Lymphocytes analysis
- Abstract
Lymphocyte subpopulations were studied in the peripheral blood, lymph nodes, and spleens in a group of 17 patients with untreated Hodgkin's disease. In 12 of 15 cases, diminished absolute levels of T-lymphocytes in the peripheral blood were found; however, this was correlated with total lymphopenia. No direct relationship between "T-lymphopenia" and diminished cellular immunity, as measured by phytohemagglutinin and pokeweed mitogen blast transformation, and delayed cutaneous hypersensitivity was demonstrated. In eight lymph nodes involved histologically by Hodgkin's disease, a preponderance of T-lymphocytes was found when compared with a group of seven hyperplastic nodes (78.2 +/- 8.9% versus 54.5 +/- 11.0%, P is less than 0.01). These latter data appear to be consistent with the hypothesis that the pathogenesis of Hodgkin's disease involves a cell-mediated immune response to a neoplastic (antigenic) element.
- Published
- 1976
43. Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura.
- Author
-
Bukowski RM, Hewlett JS, Harris JW, Hoffman GC, Battle JD Jr, Silverblatt E, and Yang IY
- Subjects
- Child, Exchange Transfusion, Whole Blood, Female, Humans, Purpura, Thrombotic Thrombocytopenic therapy
- Published
- 1976
44. VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms.
- Author
-
Mortimer J, Bukowski RM, Montie J, Hewlett JS, and Livingston RB
- Subjects
- Adolescent, Adult, Drug Resistance, Drug Therapy, Combination, Humans, Male, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Germ Cell and Embryonal drug therapy, Cisplatin therapeutic use, Doxorubicin therapeutic use, Etoposide therapeutic use, Podophyllotoxin analogs & derivatives, Testicular Neoplasms drug therapy
- Abstract
Eleven patients with recurrent and/or resistant nonseminomatous germinal cell neoplasms refractory to conventional chemotherapy were treated with the combination. VP16-213, cis-diamminedichloroplatinum, and adriamycin. One complete response, four partial responses which at surgery were benign teratomas, and six partial responses have been observed. Four patients are prolonged survivors (greater than 18 months). The possibility that this regimen may offer true salvage for refractory patients exists. Incorporation of VP16-213 into initial treatment regimens for germinal cell neoplasms is warranted.
- Published
- 1982
- Full Text
- View/download PDF
45. Case report. Aplastic anemia. Effect of antithymocyte globulin on erythroid colony formation.
- Author
-
Hamburger SA, Finke JH, Laffay DL, Bukowski RM, Hewlett JS, and Hoffman GC
- Subjects
- Child, Female, Humans, Anemia, Aplastic drug therapy, Antilymphocyte Serum therapeutic use, Colony-Forming Units Assay, T-Lymphocytes immunology
- Published
- 1978
- Full Text
- View/download PDF
46. Leukemia occurring in treated Hodgkin's disease: two neoplasms or one?
- Author
-
Sheibani K, Tubbs RR, Savage RA, Valenzuela R, Sebek BA, and Hewlett JS
- Subjects
- Adult, B-Lymphocytes analysis, Bone Marrow pathology, Diagnosis, Differential, Hodgkin Disease pathology, Humans, Leukemia, Myeloid etiology, Lymph Nodes pathology, Male, Neoplasms, Multiple Primary pathology, T-Lymphocytes analysis, Hodgkin Disease radiotherapy, Leukemia, Myeloid pathology
- Published
- 1979
- Full Text
- View/download PDF
47. Nonspecific lymphocyte cytotoxicity in patients with malignant melanoma, renal cell carcinoma, and sarcomas, and in nontumor patients.
- Author
-
Bukowski RM, Barna B, Deodhar SD, and Hewlett JS
- Subjects
- Antigen-Antibody Reactions, Cytotoxicity Tests, Immunologic, Female, Fibroblasts immunology, Humans, Male, Neoplasm Transplantation, Transplantation, Homologous, Adenocarcinoma immunology, Antilymphocyte Serum, Lymphocytes immunology, Melanoma immunology, Sarcoma immunology
- Abstract
Mononuclear cell-mediated tumor cell destruction was studied in 114 patients with malignant melanoma, renal cell carcinoma, or sarcomas, and in 122 non-tumor-bearing control subjects, with the use of the microcytoxicity assay. Cytotoxic reactions were found in all patients and control groups against melanoma, renal carcinoma, sarcoma, and fibroblast-derived cell cultures; mean levels of cytotoxicity against allogeneic combinations of tumor cells and fibroblasts were similar in tumor-bearing and control patients. These results support the concept that the reactions found represent nonspecific cytotoxicity.
- Published
- 1976
- Full Text
- View/download PDF
48. Therapy of thrombotic thrombocytopenic purpura: an overview.
- Author
-
Bukowski RM, Hewlett JS, Reimer RR, Groppe CW, Weick JK, and Livingston RB
- Subjects
- Adrenal Cortex Hormones therapeutic use, Aspirin therapeutic use, Blood Transfusion, Dextrans therapeutic use, Dipyridamole therapeutic use, Humans, Immunosuppressive Agents therapeutic use, Plasmapheresis, Renal Dialysis, Retrospective Studies, Splenectomy, Sulfinpyrazone therapeutic use, Purpura, Thrombotic Thrombocytopenic therapy
- Published
- 1981
- Full Text
- View/download PDF
49. Doxorubicin and ifosfamide combination chemotherapy in previously treated acute leukemia in adults: a Southwest Oncology Group pilot study.
- Author
-
Ryan DH, Bickers JN, Vial RH, Hussein K, Bottomley R, Hewlett JS, Wilson HE, and Stuckey WJ
- Subjects
- Acute Disease, Adolescent, Adult, Aged, Child, Doxorubicin adverse effects, Drug Therapy, Combination, Female, Humans, Ifosfamide adverse effects, Leukemia diagnosis, Male, Middle Aged, Pilot Projects, Cyclophosphamide analogs & derivatives, Doxorubicin administration & dosage, Ifosfamide administration & dosage, Leukemia drug therapy
- Abstract
The Southwest Oncology Group did a limited institutional pilot study of the combination of doxorubicin and ifosfamide in the treatment of previously treated adult patients with acute leukemia. Thirty-four patients received one or two courses of the combination. All patients had received prior chemotherapy and 32 had received prior anthracycline chemotherapy. Three patients died before their responses could be fully evaluated. Fourteen patients achieved complete remission (41%) and one patient achieved partial remission. The complete remission rate was 27% for patients with acute myeloblastic leukemia (myelomonoblastic leukemia, monoblastic leukemia, and erythroleukemia) and 89% for patients with acute lymphocytic and undifferentiated leukemia (ALL). Toxic effects included severe hematologic reactions in 33 of 34 patients, hematuria in six patients, altered sensorium in one patient, and congestive heart failure in one patient. The safety of the combination was established and toxic side effects of this therapy were tolerable. The 89% complete remission rate for previously treated patients with ALL suggests that the combination of doxorubicin and ifosfamide may be particularly effective in ALL.
- Published
- 1980
50. Prognostic factors affecting remission, remission duration, and survival in adult acute nonlymphocytic leukemia.
- Author
-
Brandman J, Bukowski RM, Greenstreet R, Hewlett JS, and Hoffman GC
- Subjects
- Adolescent, Adult, Age Factors, Aged, Drug Therapy, Combination, Female, Humans, Leukemia, Erythroblastic, Acute mortality, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Prognosis, Remission, Spontaneous, Time Factors, Antineoplastic Agents administration & dosage, Leukemia, Erythroblastic, Acute drug therapy, Leukemia, Myeloid, Acute drug therapy
- Abstract
The medical records of 94 consecutive patients with acute nonlymphocytic leukemia (ANLL) were reviewed to identify significant prognostic factors. The data were analyzed using 1) Cox's linear hazard and linear logistic models, 2) chi-square comparison of the groups living longer than 2 years and those living less than 2 years, and 3) the Gehan-Breslow test of equal survival curves. The only statistically significant finding was that the presence of promyelocytic cell type and complete remission correlated with increased survival (p less than .05), but this was negated by the small number of patients with this cell type. There was a suggestive association between higher initial hemoglobin and survival (p = .09). The Gehan-Breslow test revealed a possible difference in survival between those patients more than 51 years of age and those less than 51 (p = .10). Thus none of the commonly accepted prognostic factors in acute nonlymphocytic leukemia was definitely shown to be useful. The findings of this study support an aggressive approach toward all patients with this disease.
- Published
- 1979
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.